Advertisement

Topics

Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion—Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction

01:20 EDT 23 Aug 2017 | Wiley Biotechnology Journal

Stem cell therapy for acute myocardial infarction (AMI) seemed to be a promising therapy, however, large clinical trials brought differential outcome. It has been shown that paracrine effects of secretomes of stem cells rather than cell therapy might play a fundamental role. The present study seeks to compare cell processing protocols of clinical trials and investigate effects of differential cell culture conditions on chemokine secretion and functional effects. Different secretomes are compared regarding IL‐8, VEGF, MCP‐1, and TNF‐alpha secretion. Secretome mediated effects are evaluated on endothelial cell (HUVEC) tube formation and migration. Cardioprotective signaling kinases in human cardiomyocytes are determined by Western immunoblotting. Cells processed according to the REPAIR‐AMI protocol secrete significantly higher amounts of IL‐8 (487.3 ± 1231.1 vs 9.1 ± 8.2 pg mL−1; p < 0.05). REAPIR‐AMI supernatants lead to significantly pronounced tube formation and migration on HUVEC and enhance the phosphorylation of Akt, ERK, and CREB. Cell processing conditions have a major impact on the composition of the secretome. The REPAIR‐AMI secretome significantly enhances proangiogenic chemokine secretion, angiogenesis, cell migration, and cardioprotective signaling pathways. These results might explain differential outcomes between clinical trials. Optimizing cell processing protocols with special regards to paracrine factors, might open a new therapeutic concept for improving patient outcome. Differential results from clinical stem cell studies after acute myocardial infarction might be explained due to distinct stem cell processing protocols. This differential protocols might primarily alter the substances (i.e., secretomes) produced by stem cells and not the cells themselves. Therefore, this study gives another hint that in “stem cell therapy” not the stem cells themselves but their secretome is responsible for therapeutic effects after acute myocardial infarction.

Original Article: Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion—Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction

NEXT ARTICLE

More From BioPortfolio on "Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion—Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...